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A new study reassesses the belief that
pregnant women with breast cancer
cannot receive chemotherapy.

Redefining the risks of
chemotherapy during pregnancy

Richard Theriault is an
assistant professor
of medicine in the
Department of
Medical Oncology

When breast cancer is discovered during a pregnancy, the moment can be truly poignant for both
physician and patient. The fearful mother has many
questions: Will the baby suffer from chemotherapy?
If the treatment is delayed, will her cancer recur?
Will she live long enough to see her baby grow up?
Should she terminate her pregnancy? Or is her
husband prepared to be a single father?
Twenty-five years ago, obstetricians and oncologists were likely to recommend that a woman
terminate her pregnancy so that the standard treatment involving mastectomy, radiation, or chemotherapy could begin. Even today, many physicians
are still reluctant to give the necessary treatment to
pregnant women, said Richard Theriault, D.O., an
assistant professor of medicine in the Department of
Medical Oncology at The UniversityofTexasM. D.
Anderson Cancer Center. Much of this reluctance is
due to the lack of data on the effects that some
regimens have on fetal development. As part of the
M. D. Anderson Cancer Center's breast medical
oncology team, Theriault and other physicians are
often called upon to advise physicians around the
country on treatment of these patients. "I can
describe the regimen that we would follow, but
there are no real data to back it up," said Theriault.
Recognizing this need, he and Frankie Holmes,
M.D., who is also an assistant professor of medicine
and another member of the breast medical oncology
team, launched a study two years ago to assess the
long-term effects of chemotherapy on both the
mother and the baby. Thus far, 12 pregnant patients
with breast cancer have been entered. All received
standard doses of 5-fluorouracil, doxorubicin, and
cyclophosphamide every three to four weeks. Of the
eight mothers who have given birth, all have had
normal deliveries, and all babies have reached normal developmental milestones. "We're excited that
we've been able to give patients effective treatment

that didn't apparently affect the babies' health and,
with proper timing and scheduling of treatment,
did not increase the risks associated with delivery,"
said Theriault.
Numerous diagnostic, treatment options
available for pregnant women
For pregnant women who have breast cancer,
there are certain accepted diagnostic and treatment
options available at every stage of pregnancy,
Holmes and Theriault concurred.
As with nonpregnant patients, the majority will
first discover a lump in the breast. Diagnosis, however, is often delayed; mammograms are difficult to
interpret in pregnant women because of the increased density of breast tissue. Therefore, pregnant patients often have more advanced disease
than other women might.
Theriault and Holmes advise that, once diagnosis has been made, a complete history and detailed
physical examination be done, with attention to the
presence of bone pain, neurologic defects, and
hepatic size to determine pathologic staging. Laboratory tests to detect liver or renal dysfunction or
hematologic abnormalities can be performed with
no risk to the mother or fetus. A standard chest
radiograph poses little risk in early pregnancy if
proper shielding is used.
Ultrasound of the liver and kidneys can define
anatomic structure and organ position in relation
to the uterus and will detect the position of the
uterus in relation to any metastases. If indicated,
radiographs for bone pain and computed
tomographic brain scans for neurologic dysfunction may be conducted safely, said Theriault. Most
x-ray procedures result in fetal radiation doses of
less than 5 cGy. There has been little or no reported increase in incidence of congenital malformations, growth retardation, or fetal death caused
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'-The mother walked in for
her appointment, wearing her wig
and carrying her little
fuzzy-headed baby"
•

Frankie Hofmes is an
assistant professor
of m edicine in the
Department of

Medical Oncology

by use of nuclear medicine, he said, but advised that
such procedures should be used only when their
outcome will influence treatment-related decisions.
"The need to know must be sufficient to justify the
risk of radiation exposure and, of course, the fetus
should be shielded whenever possible."
Therapy for the primary tumor should be considered in light of clinical staging and anticipated
outcome. The options include surgery, chemotherapy, and, in extremely advanced cases, termination of pregnancy.
With modern anesthetic techniques, surgery is
quite safe, said Theriault. If tumors are known to be
surgically resectable and there are no known
metastases, a modified radical mastectomy with axillary node sampling can be recommended. Only I%
of mastectomies result in spontaneous abortion;
when compared with the benefits of disease control
and information to be gained from histologic analysis, the surgery is well advised. However, lumpectomy
with local radiation "remains an investigational
therapy in pregnant patients," he added. It is generally not recommended because of lack of data on
radiation's effects on the fetus. Radiation therapy is
widely considered to be harmful to the fetus during
any stage of pregnancy.
Pregnancy does not alter disease progression
Termination of pregnancy as an option is recommended in cases of advanced disease, whe_n very
aggressive treatment is needed to save the mother.
At that juncture, the patient and husband must
decide whose life they wish to save. "We generally
choose to treat the mother, unless that is not the
parents' desire," said Theriault. Some physicians
recommend termination because the elevated hormone levels associated with pregnancy might stimulate tumor growth. Theriault has found extensive
documentation to the contrary. "The pregnancy
itself does not alter the course of breast disease, and
termination of pregnancy will not improve a
patient's chances of survival or cure," he said.
Because the effects of chemotherapy on the fetus
and mother remain undocumented, fetal development during each stage of pregnancy has become a

•
critical factor in determining whether chemotherapy
is advised.
Treatment options are few during the early months
of pregnancy. Mastectomy is very appropriate and
very safe, but chemotherapy is not advised. "The
first trimester is very tender. We try to avoid chemotherapy during this time because fetal organs are
developing," said Theriault. "Major fetal damage
can occur; the risks are just too high." For women
with stage I or II disease, chemotherapy can be
delayed up to 12 weeks without affecting the
mother's prognosis, research has shown. However,
their advice is different for patients with advancedstage disease or inflammatory breast cancer, a rapidly progressive disease. The aggressive chemotherapy necessary to save the mother may threaten
the fetus' life or development. Even that effort may
be futile, since the advanced stages of disease offer
slim chances that the mother will survive. A choice
often must be made between keeping the mother
alive long enough to give birth or aggressively trying to save the mother only.
When early-stage breast cancer is discovered during the second trimester, the patient should have a
mastectomy with adjuvant chemotherapy, as appropriate. By that time, the major fetal organs have been
formed and the risk of major fetal malformation is
significantly reduced. "It appears that chemotherapy
is very safe in the second and third trimesters; babies
may have low birth weight but all have been normal
and healthy," said Theriault. Chemotherapy might
cause miscarriage because it reduces white cell counts,
but that risk is small and can be avoided by properly
timing the last dose so that white cell counts are high
enough at birth. Patients with advanced disease may
need to consider termination of pregnancy to allo~
for more aggressive treatments.
By the third trimester, the risks of chemotherapy to both mother and fetus have decreased
significantly. The fetus is nearly fully developed,
and standard chemotherapy regimens can be safely
adminstered either before or after mastectomy .
Patients with advanced disease may be advised to
have labor induced so that aggressive treatments
can begin.
continued on page 7
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The overall cure rate for human cancer now approaches
5 0%. Surgery and radiotherapy, alone or in combination,
still account for the majority of cures. Radiotherapy, the
first nonsurgical cancer treatment, remains one of the
most fertile areas for research and application in cancer
treatment.
Dr. Gilbert H. Fletcher is uniquely qualified to write on
the evolution of modern radiotherapy. Leader of the team
that designed, built, and used the first American cobalt-60
radiation therapy delivery unit, he pioneered research in
radiotherapy and radiobiology. He has trained a generation of radiation therapists, physicists, and radiobiologists.
Dr. Fletcher led the radiotherapy program at The University of Texas M. 0. Anderson Cancer Center from its

creation in 194 7 until his partial retirement in 1981, when
he gave up administrative duties to return once again to
teaching, writing, research, and patient care.
Dr. Fletcher is a highly respected and much honored
international leader in radiation oncology and a great
observer of both science and philosophy. He is a significant
player in both the history and future of modern radiotherapy. In this article, he traces the growth of
radiotherapeutic theory and application, highlighting some
of the important events in the development of our current
approaches to successful cancer treatment.
-James M. Bowen, Ph.D., Professor
of Virology, Vice President
for Academic Affairs

Significance of cancer volume
in radiotherapy
By Gilbert H. Fletcher, M.D.

In the 1950s, cobalt-60 units, million-volt generators, linear accelerators, and betatrons were
made available for clinical use. A cobalt-60 unit
was developed at The University of Texas M. D.
Anderson Cancer Center ( then called the The
University of Texas M. D. Anderson
Hospital and Tumor Institute) in cooperation with the Oak Ridge Institute of Nuclear Studies, one of the
Atomic Energy Commission institutes
devoted to the peaceful use of atomic

During the first half of the: century, irradiation
was tried in all tumors. Small squamous cell
carcinomas of the oral cavity and of the uterine
cervix were successfully treated by
brachytherapy. Cancers of the skin
could be cured by external irradia tion, and lymphomas could also to
some extent be controlled by irradiation. These tumors were considered
"radiosensitive." On the other hand,
large tumors-either squamous cell
:::~:;::;1::;:~::~~~i:~:~n:o~:
sible to give higher doses to deepcarcinoma, adenocarcinoma of the
seated tumors and to use irradiation
breast, the malignant tumors of the
salivary glands, or soft tissue sarcomafreely for elective treatment of cliniGilbert H. Fletcher,
when irradiated, showed very limited,
cally uninvolved lymphatic areas and
clinical professor of
if any, response.
radiotherapy, Department postoperatively after removal of gross
At mid-century, the practice of ra- of Clinical Radiotherapy cancer to treat residual disease.
diotherapy and its place in the manIn the ensuing years, several
agement of the cancer patient was based on three analyses were made of the results obtained with
rigid concepts: First, there was an "all or none megavoltage irradiation used either as primary
cancerocidal dose," irrespective of the cancer treatment for the tumors, as elective irradiation
volume. In world-famous institutions like the of potentially involved lymphatic areas, or in
Christie Hospital in Manchester, United King- association with surgical procedures.
dom, the same dose was given to all lesions.
Second, a homogeneous radiation dose had to be Relationship between cancer volume and
given to the whole target volume . And third, the tumor-controlling dose
surgical procedure had to be radical and was
The analyses showed that, if there is no gross
called a "cancerwise procedure."
disease in areas accessible to inspection and palpaBecause of the lack of skin sparing of kilovoltage tion, lesser doses ofirradiation (e.g., 50 Gy) were
radiation, skin sequelae were severe. Neither the adequate to eradi ca te occult disease, i.e., su bclinical
combination of irradiation and surgery nor the disease. As the tumor size increases, higher doses
use of large -volume irradiation, such as elective were necessary to obtain significant control rates.
irradiation of clinically uninvolved lymphatic ar- Irradiation is most effective in controlling microeas, could be done freely.
scopic disease. Conversely, surgery is effective,
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'-At mid-century, the practice of
radiotherapy and its place in the
management of the cancer patient was
based on three rigid concepts"
•
provided the tumor is resectable, in removing
gross cancer but too often fails to remove, irrespective of how radical the procedure is, the
diffuse microscopic disease around the gross mass.
Therefore, the two modalities can often be used
in a complementary mode: surgery to remove
gross cancer and pre- or postoperative irradiation
to eradicate microscopic disease around the gross
mass. As an important corollary, the classical radical surgical procedures, such as radical neck dissection or radical mastectomy, need not be performed. The surgical goal should be to remove
only gross disease. It was also found that the
combined treatment could be more effective than
the radical surgical procedure. Conservative surgical procedures combined with modest doses of
irradiation may leave the organs less mutilated,
thereby affording a better quality of life.
These concepts have revolutionized the practice
of surgery and radiotherapy in many clinical situations, even in tumors previously thought to be
radioresistant. For example, the sacrifice of the
facial nerve had been part of the surgical proce-

The beneficial effects of the complementary use of conservative surgery with
radiation. A 40-year-old woman presented with pain in the right arm on motion.
A 2x4-cm subcutaneous mass just anterior to the head of the humerus (above)
was excised on November 1 7, 1972. The mass was diagnosed as high-grade
fibrosarcoma. She received postoperative irradiation. In 1976, the patient had
excellent arm function (right). In 1986, the patient was disease free and still had
excellent arm function. Reprinted with permission from Fletcher GH, Textbook of
Radiotherapy, 3rd ed., Philadelphia: Lea & Febiger, 1980, p. 925.
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<lure to resect highly malignant tumors of the
parotid, since the facial nerve runs through the
superficial lobe of the parotid gland. With postoperative irradiation, however, one can preserve
the facial nerve. Similarly, with small-volume
breast cancers, which are detected more and
more by mammography, tumor excision followed by irradiation yields control rates comparable to those of radical mastectomy. T he cosmetic results are usually excellent.
The treatment of soft-tissue sarcomas at the
M. D. Anderson Cancer Center has been, since
the 1960s, excision of gross disease, whenever
possible, followed by postoperative irradiation.
Preoperative irradiation has been used in
unresectable tumors. Results have shown control rates superior to the ones obtained by the
most radical operations . Furthermore, it is a
limb-saving procedure. ■
Physicians who desire additional informati on may
write Gilbert H . Fletcher, M .D ., D epartment of Clinical
Radiotherapy, Box 97, The University of Texas M. D.
Anderson Cancer Center, 1515 H o lcom be Boulevard,
Houston , T exas 77030, o r call (7 13 ) 792-3445 .
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touching the patient, thus providing the safest
treatment possible.
Pancreatic Cancer
In light of surgery's ineffectiveness, changing
continued from page 8
treatment protocols seems a logical step, but
been devascularized, and ( 3) implantation and doing so addresses only the purely medical issue
dissemination of tumor cells during laparotomy of cure. It does not, in itself, address what Evans
may be prevented by preoperative chemoradiafeels is a stifling sense of hopelessness that surtion, thus reducing the risk of disease recurrence rounds pancreatic cancer, a hopelessness that
in the peritoneum.
perhaps has been engendered by the medical
"Preoperative chemoradiation is also an imporcommunity's tacit acceptance of the disease's
tant stress test," Evans said. "If the patient cannot fatality and by the low volume of patients.
withstand chemoradiation, it is certain he would
For Evans, these two factors are mutually reinnot withstand major surgery."
forcing and tend to deteriorate, though subtly,
Preliminary data from 10 patients who underthe momentum ofresearch. Health-care providwent surgery after chemoradiation suggest that ers like to help as many patients as possible, but
the concern over tissue integrity is not a signifibecause of the lack of effective treatment for
cant contraindication to preoperative radiation.
pancreatic cancer, many patients are sent to their
A small pancreatic leak occurred in one patient, local hospital for palliative care. As a result, no
and the leak resolved spontaneously. Based on center has a consistent patient volume. The
these data, Evans and his colleagues (Tyvin Rich, sporadic patient becomes, then, an anomaly. "If
M.D ., Department of Clinical Radiotherapy, J affer you see only one case every two or three months,
Ajani, M.D., Department of Medical Oncology, it is very difficult to energize people to work
and John Hoffman, M. D., from the Fox Chase
toward a goal," Evans said.
Cancer Center) hope to initiate a multi-instituHis solution was to develop an organized aptional Radiotherapy Oncology Group (RTOG) proach to pancreatic cancer treatment, one based
study, which will also evaluate a second compoon a new protocol, driven by consistent patient
nent of the protocol, intraoperative radiotherapy.
volume, and supported by every member of the
The rationale behind intraoperative radiotherapy treatment team.
is to improve local tumor control by irradiating
Two key departments in this approach are Dithe tumor bed or residual tumor while sparing agnostic Imaging and Pathology. "We work very
surrounding tissue. Studies at the Mayo Clinic closely with Dr. Chuslip Charnsangavej in
and the Massachusetts General Hospital suggest Diagnostic Imaging. Since he understands our
that such treatments can reduce the rate of retreatment approach and objectives, he can comcurrence at the primary tumor site. The therapy plete a diagnostic workup rapidly and efficiently."
is well tolerated and improves pain control. UnAnother key member is Ruth Katz, M.D., a
der the direction of Rich, the M. D. Anderson cytologist in the Department of Pathology. UsCancer Center was the first institution in the ing high-resolution thin-cut computed
United States todevelop.adedicatedintraoperative tomography ( CT), Katz, working with
radiotherapy suite in a central operating room.
Charnsangavej, will perform a transabdominal
Linear accelerators have also been installed in fine-needle aspiration, ifindicated. "The result of
operating rooms at the Mayo Clinic and in several this close teamwork is a much faster diagnosis.
hospitals in Germany. This set-up reduces treatThe patient can come in on Wednesday, have a
~enLtime_for__two~ons :__(_L)~the_JineaLace_~-~-diagnosis by Frida}', and beg=
i n~ t~re=a=t=m=e=n=t~ o=n~ - - - - - - - - - - erator, as opposed to conventional orthovoltage Monday," Evans said.
irradiation devices, can deliver a higher dose in a
Such collaboration is not limited to, the clinic.
shorter time, and (2) the patient does not have to Evans works closely with two pathologists, Karen
be moved from surgery to the radiation therapy Cleary, M.D., and John Connelly, M.D., who
department. Total treatment time, including inrigorously classify all tumor specimens. "To assess
strument set-up and delivery of intraoperative treatment, it is essential to have a complete paradiation, averages 30-45 minutes.
thology report," Evans said. "Cleary and Connelly
"Another advantage is our laser-guided 'dock- ensure that all pertinent criteria are evaluated and
ing' system, which was developed by Dr. Rich, recorded. All pancreatic cancer is not the same.
Mr. Tim Ochran, and Siemens Medical Laborato- Tumor size, degree of differentiation, the presries," Evans said. Using lasers, the treatment cone ence of vascular, lymphatic, or perineural invacan be aligned with the radiation field without sion, and careful assessment of all margins are
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lntraoperative radiotherapy
unit, operating table,
and treatment cone. After
chemoradiation, pancreatic
cancer patients undergoing the
new M . D. Anderson protocol
receive intraoperative radiotherapy at this facility,
the fi rst of its kind in
the United States.

analyzed for every tumor specimen." Evans is also
collaborating with basic scientists Marsha Frazier,
Ph.D., and David Byrd, M .D.
"This is perhaps the most exciting area," Evans
said. Frazier and Byrd are looking at fundamental
basic science issues. For example, one crucial
hindrance to past studies of pancreatic cancer has

been a lack of experimental models . Frazier is
attempting to develop a transgenic mouse model
for pancreatic duct cell cancer, since most human
tumors are ductal in origin. The transgenic animals will be genetically programmed to develop
pancreatic duct cell tumors at a fairly precise time
point in the animal's life. Because of the reproducibility of the model, it will be useful in studying the early events in tumor development and
should therefore provide important information
regarding the prevention and early detection of
the disease . Frazier is also trying to identify gene
markers of pancreatic cancer that would allow
earlier detection . Considering that many patients
present with advanced disease, such a marker
would be an important step toward improving
survival.
Byrd has begun a comprehensive tumor bank of
primary and metastatic pancreatic tumor specimens. Some fresh specimens are frozen for future
DNA, RNA, and immunohistochemical analysis.
Other specimens are cultured and used to inoculate athymic mice, the intent being to develop an
in vivo model of liver metastasis and peritoneal
carcinomatosis. In in vitro studies, Byrd is also
testing immunotherapeutic approaches and studying stromal/ pancreatic tumor cell interaction.
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Such basic research efforts are essential, but
there is also another side that Evans believes is
just as important. It is very easy to reduce
patients to statistics, to gauge a treatment solely
based on numbers, to think of progress only in
terms of long-term survival. That temptation is
especially powerful when caring for pancreatic
cancer patients, who have so few treatment options. But such advances can be pyrrhic unless
weighed against the treatment's effect on quality
of life . (Evans intends to gauge each patient's
emotional response during the experimental
chemoradiation/intraoperative radiotherapy protocol using a quality-of-life study.)
For Evans, every member of the health -care
team should be concerned about quality of life,
but especially important to him are such ancilla1y
services staff as social workers and dietitians.
"Two people who are crucial to this effort arc
social worker Judy Weil, M.S.W., and dietitian
Dana Martin, R.D., C.N.S.D. Both Weil and
Martin have a specific interest in pancreatic cancer;
they know what these patients are facing and are
familiar with their needs. It is very important for
patients to know that their caregivers understand
their disease," Evans said.
Such patients certainly n,eed hope, and that is
one thing Evans hopes the new prot ocol will
instill, but some patients facing a terminal disease
also need to know that something is being done,
that they are not going to die without a fight, and
that there are health-care providers who are
genuinely and actively trying to cure their disease.
We should not underestimate the psychological benefit of such a treatment environment, one
based on an active pursuit of cure rather than a
tacit acceptance of death. "Patients come here
upset; they're pessimistic; they've been told that
nothing can be done for them," Evans said. "But
they find that we're interested in their disease,
that we have an organization designed to treat
them . They know they may die, but they also
know that they are being seen by people who
come to work each day to treat pancreatic cancer,
and that the knowledge gained from the experimental treatment they receive now may ultimately
benefit someone else later."
In the 1950s and 1960s, any pediatrician treating
leukemia was faced with the same challenge:
Before attempting to find a cure, one first had to
overcome the pervasive pessimism against such an
attempt. But with action, hope, and small suc cesses, the promise of cure was finally achieved for
a large percentage of patients . Whether Evans'
and his colleagues' commitment to action will
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have the same result is still in question, but
without it, pancreatic cancer will certainly remain
an incurable disease. ■
Physicians who desire additional information may
write Douglas B. Evans, M.D., Department of General
Surgery, Box 106, The University of Texas M. D.
Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, Texas 77030 , or call (713) 794-4324.

Chemotherapy during
pregnancy
continued from page 2

N onnal deliveries, normal babies
after treatment
Holmes has seen four patients in the last year give
birth to normal babies. Of these, two cases represent
typical decisions that these women must make.
One mother in her late 30s was in the middle of
her second trimester when breast cancer was diagnosed. Her chemotherapy extended from the end of
that trimester until three weeks before her estimated
due date. Holmes had developed this schedule so
that she would give birth when her white cell count
was normal. The baby was born on schedule, and
"it was a perfectly normal delivery," said Holmes.
Both mother and baby are fine.
Not all mothers are so lucky. A 28-year-old
woman came to H olmes when she was 18 weeks
pregnant, and she had to learn the hard truth that
the breast cancer she thought she had overcome two
years earlier had recurred. "Other doctors had advised abortion because she was a high-risk case. She
wanted my opinion," said Holmes. "It was obvious
that she would not live a normal life expectancy, and
she had to decide whether she wanted to fight the
cancer with aggressive treatment or whether she
wanted the baby. She decided she wanted this baby."
The patient was given chemotherapy and the tumor
disappeared, so the treatment ended about six weeks
before her delivery. "She did well until after the
delivery," said Holmes. At that time the patient was
given the anti-hormone drug tamoxifen, a treatment
that cannot be given during pregnancy because itinterrupts the sequence of hormones necessary to
maintain the placenta and uterus. She later developed a recurrence in the liver. The patient almost
died in October and "is living from day to day," said
Holmes. Her baby, however, is healthy.
While chemotherapy can be safe for both mother
and fetus during the second and third trimesters, it
does have certain short-term side effects beyond the
normal nausea and hair loss. Some mothers are
distressed to find that they are unable to nurse their
babies. Chemotherapy prevents normal breast development that allows milk production after delivery.

The long-term side effects remain to be determined; although chemotherapy has been available
in aggressive combinations since 1974, it has not
been used as widely as it is now, said Holmes. "We
don't have 25 years of experience in monitoring its
effects on the growing fetus. At least in the shortterm, there don't seem to be any differences in fetus
growth and development."
Chromosome status and physical/cognitive
milestones to be tracked
Questions remain. Are the chromosomes of these
babies more susceptible to damage by environmental carcinogens? "There's a question of fragility,
because they've already been exposed to one type of
injury," said Holmes. Do the children reach their
normal milestones within the appropriate ages?
Would their prognosis be different if the mother had
been nearing the end of her child-bearing years,
when chromosomal damage is a higher risk?
Holmes and Theriault said that the babies they
have seen were born normally and are developing
normally. "It's a good sign," said Holmes. They plan
to follow all the babies through their childhood and
adolescence, conducting chromosome studies and
monitoring achievement of physical and cognitive
goals. New patients and their babies will be added to
the study when they are seen by the breast medical
oncology group.
For Holmes, the hope increases with every patient
who gives birth to a baby with hair. "All our patients
are bald because of the doxorubicin, but the babies
are born with lots of hair," she said. "So obviously
the doxorubicin doesn't cross the placenta in sufficient amounts to cause the baby to be bald." She
recalls her first experience with this phenomenon.
"The mother walked in for her appointment, wearing her wig and carrying her little fuzzy-headed
baby. Obviously pleased that her baby had suffered
no ill effects from the drugs, she just kept rubbing
that baby's head," Holmes concluded, with a satisfied smile. ■
Physicians who desire additional information may
write Frankie Holmes, M.D ., or Richard Theriault, D.O.,
Department of Medical Oncology, Box 95, The University
of Texas M. D . Anderson Cancer Center, 1515 Holcombe
Boulevard, Houston, Texas 77030, or call (713 ) 792-2817.
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Renewing the assault on pancreatic cancer

Douglas B. Evans is chief of
the Pancreatic Tumor
Section in th e Department
of General Surgery

All cancer patients must come to grips with fear,
but those with pancreatic cancer al o face fru tration. Treatment options are few and ineffective.
Surgery confers a slight long-term survival ad antage, but only 10-20% of patients are eligible, and
the operation is extensive, requiring 8-10 week
of recuperation. The presumption that "nothing
can be done," that they must await d ath rath r
than attempt cure, is something that pancreatic
cancer patients are often asked to ace pt.
Douglas B. E ans, M.D., a surgeon in the
Department of General Surgery at The ni er i
ofTexas M . D. Anderson Cancer Center i familiar
with the pessimism, but his respon e i not re ignation, but action. As chief of the Pancreati Tumor Section, he is de eloping a team of radiologi t
cytologists surgeons medical oncologi ts radiotherapists, pathologists basic cienti ts nurs
ocial v orkers and dietitians for a renev ed assault on
pancreatic cancer.
"A fe
ears ago no que tion v ere being
asked, no ongoing protocol being tudied. In an
effort to counter the hopele ne that had per-
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